Between September 20, 2011, and July 8, 2014, a total of 137 patients were enrolled in the phase 1/2 study and received brigatinib at doses ranging from 30 mg to 300 mg daily; 79 patients had ALK+ NSCLC. Here, ALK is linked to non-small cell lung carcinoma.